Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Gains from Sales and Divestitures: 2017-2024

  • Rhythm Pharmaceuticals' Gains from Sales and Divestitures rose 170.60% to $581,346 in Q4 2024 from the same period last year, while for Dec 2024 it was $581,346, marking a year-over-year increase of 170.60%. This contributed to the annual value of $581,346 for FY2024, which is 170.60% up from last year.
  • According to the latest figures from Q4 2024, Rhythm Pharmaceuticals' Gains from Sales and Divestitures is $581,346, which was up 170.60% from $214,837 recorded in Q4 2023.
  • Rhythm Pharmaceuticals' 5-year Gains from Sales and Divestitures high stood at $581,346 for Q4 2024, and its period low was $27,583 during Q4 2021.
  • Moreover, its 3-year median value for Gains from Sales and Divestitures was $214,837 (2023), whereas its average is $318,243.
  • Data for Rhythm Pharmaceuticals' Gains from Sales and Divestitures shows a peak YoY skyrocketed of 474.80% (in 2022) over the last 5 years.
  • Over the past 4 years, Rhythm Pharmaceuticals' Gains from Sales and Divestitures (Quarterly) stood at $27,583 in 2021, then spiked by 474.80% to $158,546 in 2022, then soared by 35.50% to $214,837 in 2023, then spiked by 170.60% to $581,346 in 2024.
  • Its Gains from Sales and Divestitures stands at $581,346 for Q4 2024, versus $214,837 for Q4 2023 and $158,546 for Q4 2022.